

# Sotirios G Papageorgiou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4012569/publications.pdf>

Version: 2024-02-01

133  
papers

2,380  
citations

257101

24  
h-index

253896

43  
g-index

135  
all docs

135  
docs citations

135  
times ranked

3411  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. <i>Advances in Hematology</i> , 2012, 2012, 1-15.	0.6	183
2	The role of microRNAs in normal and malignant hematopoiesis. <i>European Journal of Haematology</i> , 2010, 84, 1-16.	1.1	169
3	Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. <i>Annals of Oncology</i> , 2008, 19, 1992-1999.	0.6	147
4	Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). <i>Leukemia and Lymphoma</i> , 2006, 47, 2140-2146.	0.6	128
5	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care. <i>Oncologist</i> , 2012, 17, 239-249.	1.9	105
6	Phosphatidylinositol 3-Kinase Catalytic Subunit $\beta$ Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2009, 15, 5724-5732.	3.2	99
7	Primary adrenal lymphoma presenting as Addison's disease: case report and review of the literature. <i>Annals of Hematology</i> , 2004, 83, 460-463.	0.8	58
8	Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome. <i>British Journal of Dermatology</i> , 2007, 156, 1379-1380.	1.4	43
9	PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. <i>Leukemia</i> , 2016, 30, 238-242.	3.3	43
10	A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4. <i>Haematologica</i> , 2007, 92, 1343-1350.	1.7	39
11	The Novel Member of the BCL2 Gene Family, BCL2L12, Is Substantially Elevated in Chronic Lymphocytic Leukemia Patients, Supporting Its Value As a Significant Biomarker. <i>Oncologist</i> , 2011, 16, 1280-1291.	1.9	39
12	Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. <i>Microorganisms</i> , 2020, 8, 1885.	1.6	39
13	Monoclonal gammopathies in B-cell non-Hodgkin's lymphomas. <i>Leukemia Research</i> , 2003, 27, 505-508.	0.4	37
14	Non-Hodgkin's Lymphomas in Greece according to the WHO Classification of Lymphoid Neoplasms. <i>Acta Haematologica</i> , 2005, 113, 97-103.	0.7	32
15	MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis. <i>Disease Markers</i> , 2017, 2017, 1-10.	0.6	32
16	Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2013, 37, 251-258.	0.4	31
17	MicroRNAs: Tiny Regulators of Gene Expression with Pivotal Roles in Normal B-Cell Development and B-Cell Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 593.	1.7	31
18	Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. <i>Hematological Oncology</i> , 2013, 31, 10-17.	0.8	30

#	ARTICLE	IF	CITATIONS
19	Epigenetic alterations and microRNAs. <i>Epigenetics</i> , 2013, 8, 561-570.	1.3	30
20	Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2018, 70, 1-7.	0.4	29
21	Antiphospholipid syndrome: a predisposing factor for early onset HELLP syndrome. <i>Rheumatology International</i> , 2007, 28, 171-174.	1.5	28
22	Identification of a novel tRNA-derived RNA fragment exhibiting high prognostic potential in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019, 37, 498-504.	0.8	28
23	KLKB1 mRNA overexpression: A novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia. <i>Clinical Biochemistry</i> , 2015, 48, 849-854.	0.8	27
24	Extracorporeal photopheresis in refractory chronic graft-versus-host disease: The influence on peripheral blood T cell subpopulations. A study by the Hellenic Association of Hematology. <i>Transfusion and Apheresis Science</i> , 2012, 46, 181-188.	0.5	26
25	mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (HIF1A): An independent predictor of poor overall survival in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2017, 53, 65-73.	0.4	26
26	Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 336-348.	0.8	25
27	Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. <i>European Journal of Haematology</i> , 2005, 75, 124-129.	1.1	24
28	The role of miRNAs in endometrial cancer. <i>Epigenomics</i> , 2015, 7, 951-959.	1.0	24
29	Identification of a novel, internal tRNA-derived RNA fragment as a new prognostic and screening biomarker in chronic lymphocytic leukemia, using an innovative quantitative real-time PCR assay. <i>Leukemia Research</i> , 2019, 87, 106234.	0.4	24
30	Hypoxia-inducible factors in mantle cell lymphoma: implication for an activated mTORC1/HIF-1 pathway. <i>Annals of Hematology</i> , 2011, 90, 315-322.	0.8	23
31	A novel, mitochondrial, internal tRNA-derived RNA fragment possesses clinical utility as a molecular prognostic biomarker in chronic lymphocytic leukemia. <i>Clinical Biochemistry</i> , 2020, 85, 20-26.	0.8	23
32	Multifocal Extranodal Non-Hodgkin Lymphoma: A Clinicopathologic Study of 37 Cases in Greece, a Hellenic Cooperative Oncology Group Study. <i>Oncologist</i> , 2005, 10, 734-738.	1.9	22
33	Lobomycosis: A case from Southeastern Europe and review of the literature. <i>Journal of Dermatological Case Reports</i> , 2012, 6, 65-9.	1.1	22
34	Red Blood Cell Abnormalities as the Mirror of SARS-CoV-2 Disease Severity: A Pilot Study. <i>Frontiers in Physiology</i> , 2021, 12, 825055.	1.3	22
35	The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas. <i>Advances in Hematology</i> , 2012, 2012, 1-13.	0.6	21
36	Cell cycle and apoptosis regulatory gene expression in the bone marrow of patients with de novo myelodysplastic syndromes (MDS). <i>Annals of Hematology</i> , 2010, 89, 349-358.	0.8	20

#	ARTICLE	IF	CITATIONS
37	Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2017, 60, 74-81.	0.4	18
38	MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 658-667.	0.6	18
39	The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas. <i>Biomedicines</i> , 2021, 9, 333.	1.4	18
40	Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression. <i>Leukemia Research</i> , 2010, 34, e254-e256.	0.4	17
41	Acute myelogenous leukemia with tetrasomy 8 is a disease with a poor prognosis. <i>Cancer Genetics and Cytogenetics</i> , 2005, 161, 78-81.	1.0	16
42	Analysis of apoptosis regulatory genes expression in the bone marrow (BM) of adult de novo Myelodysplastic Syndromes (MDS). <i>Leukemia Research</i> , 2008, 32, 61-69.	0.4	16
43	Abnormalities of DNA repair mechanisms in common hematological malignancies. <i>Leukemia and Lymphoma</i> , 2011, 52, 567-582.	0.6	16
44	Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation. <i>Leukemia Research</i> , 2013, 37, 175-182.	0.4	16
45	The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine. <i>Clinical Cancer Research</i> , 2016, 22, 1958-1968.	3.2	16
46	mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 315-24.	1.4	15
47	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. <i>Oncologist</i> , 2021, 26, 597-609.	1.9	15
48	Simultaneous occurrence of colonic adenocarcinoma and MALT lymphoma: A series of three cases. <i>World Journal of Gastrointestinal Oncology</i> , 2012, 4, 89.	0.8	15
49	A novel p27 gene mutation in a case of unclassified myeloproliferative disorder. <i>Leukemia Research</i> , 2005, 29, 229-231.	0.4	14
50	Allogeneic stem cell transplantation as treatment for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2006, 38, 721-727.	1.3	14
51	Extracorporeal photopheresis in the treatment of chronic graft-versus-host disease. The Hellenic experience: A study by the Hellenic association of hematology. <i>Transfusion and Apheresis Science</i> , 2012, 46, 173-180.	0.5	14
52	Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine. <i>Blood Cancer Journal</i> , 2014, 4, e187-e187.	2.8	14
53	Rhodotorula mucilaginosa associated meningitis: A subacute entity with high mortality. Case report and review. <i>Medical Mycology Case Reports</i> , 2014, 6, 46-50.	0.7	14
54	The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacitidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Hematological Oncology</i> , 2018, 36, 693-700.	0.8	14

#	ARTICLE	IF	CITATIONS
55	Mutational and methylation analysis of the cyclin-dependent kinase 4 inhibitor (p16INK4A) gene in chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2006, 76, 230-236.	1.1	13
56	Hypermethylation of the p15INK4B gene promoter in B-chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2007, 82, 824-825.	2.0	13
57	Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: Promising results in marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 68-74.	0.6	13
58	Increased expression of phosphorylated NBS1, a key molecule of the DNA damage response machinery, is an adverse prognostic factor in patients with de novo myelodysplastic syndromes. <i>Leukemia Research</i> , 2013, 37, 1576-1582.	0.4	13
59	Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the "real life" setting: A single center observational study. <i>Hematology</i> , 2016, 21, 34-41.	0.7	13
60	Rosuvastatin-Induced Thrombocytopenia. <i>Southern Medical Journal</i> , 2010, 103, 676-678.	0.3	12
61	Chronic myelomonocytic leukemia treated with 5-azacytidine " results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. <i>Leukemia and Lymphoma</i> , 2019, 60, 1721-1730.	0.6	12
62	A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis. <i>Microorganisms</i> , 2021, 9, 806.	1.6	12
63	Expression analysis of proteins involved in the non homologous end joining DNA repair mechanism, in the bone marrow of adult de novo myelodysplastic syndromes. <i>Annals of Hematology</i> , 2010, 89, 233-239.	0.8	11
64	The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL). <i>Bone Marrow Transplantation</i> , 2013, 48, 1271-1278.	1.3	11
65	Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110139.	1.1	11
66	A 3' tRNA-derived fragment produced by tRNA LeuAAG and tRNA LeuTAG is associated with poor prognosis in B-cell chronic lymphocytic leukemia, independently of classical prognostic factors. <i>European Journal of Haematology</i> , 2021, 106, 821-830.	1.1	11
67	The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacytidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. <i>American Journal of Hematology</i> , 2018, 93, 895-901.	2.0	10
68	Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. <i>Annals of Hematology</i> , 2021, 100, 2279-2292.	0.8	10
69	Preservation of Fertility in Women Undergoing Reduced-Intensity Conditioning Allogeneic Transplantation With a Fludarabine-Based Regime. <i>Transplantation</i> , 2012, 94, e29-e30.	0.5	9
70	BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era. <i>Leukemia and Lymphoma</i> , 2016, 57, 2199-2203.	0.6	9
71	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1383-1392.	0.8	9
72	Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096612.	1.1	9

#	ARTICLE	IF	CITATIONS
73	Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab. <i>Cancers</i> , 2022, 14, 1917.	1.7	9
74	Chronic Neutrophilic Leukemia: A Comprehensive Review of Clinical Characteristics, Genetic Landscape and Management. <i>Frontiers in Oncology</i> , 2022, 12, 891961.	1.3	9
75	Immunophenotypic Profile of CD34+ Subpopulations and Their Role in the Diagnosis and Prognosis of Patients with De Novo, Particularly Low Grade Myelodysplastic Syndromes. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 73-82.	0.7	7
76	Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3 <sup>+</sup> T cells represents a potential antitumor mechanism of azacitidine. <i>Blood Advances</i> , 2021, 5, 129-142.	2.5	7
77	Treatment of intermediate and advanced stage Hodgkin's disease with modified baseline BEACOPP regimen: a Hellenic Co-operative Oncology Group Study. <i>European Journal of Haematology</i> , 2003, 71, 257-262.	1.1	6
78	Prognostic significance of monoclonal gammopathy in diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2019, 37, 634-637.	0.8	6
79	The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry. <i>Cancer Medicine</i> , 2019, 8, 2056-2063.	1.3	6
80	Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience. <i>Advances in Hematology</i> , 2019, 2019, 1-5.	0.6	6
81	Chronic myelomonocytic leukemia - a review. <i>Expert Review of Hematology</i> , 2021, 14, 59-77.	1.0	6
82	Gastric involvement in patients with primary mediastinal large B-cell lymphoma. <i>Anticancer Research</i> , 2014, 34, 6717-23.	0.5	6
83	Deletion (11)(q13) as the sole anomaly in myeloid malignancies: four new cases and a short review. <i>Annals of Hematology</i> , 2004, 83, 153-155.	0.8	5
84	Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights. <i>Pathology Research and Practice</i> , 2016, 212, 1194-1198.	1.0	5
85	Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate. <i>PLoS ONE</i> , 2017, 12, e0170186.	1.1	5
86	Rare diseases of bone. <i>EFORT Open Reviews</i> , 2018, 3, 381-390.	1.8	5
87	Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS).. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019045.	0.5	5
88	Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacytidine: Results From the Hellenic 5-Azacytidine Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 114-121.	0.2	5
89	Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Journal of Geriatric Oncology</i> , 2020, 11, 121-124.	0.5	5
90	Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma. <i>Viruses</i> , 2021, 13, 1844.	1.5	5

#	ARTICLE	IF	CITATIONS
91	Acute apenditis in patient with acute promyelocytic leukemia. <i>Leukemia Research</i> , 2011, 35, e4-e5.	0.4	4
92	CD20 expression in angioimmunoblastic T cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 345-347.	0.6	4
93	The role of miRNAs and epigenetic mechanisms in primary gastric mucosa-associated lymphoid tissue lymphoma. <i>Future Oncology</i> , 2016, 12, 1587-1593.	1.1	4
94	The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes. <i>British Journal of Haematology</i> , 2021, 192, 978-987.	1.2	4
95	Absence of p16 and p27 gene rearrangements and mutations in de novo myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2005, 75, 193-198.	1.1	3
96	Analysis of FLT3 gene mutations in de novo myelodysplastic syndromes. FLT3 internal tandem duplication detected in a case of refractory anemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 2437-2440.	0.6	3
97	CNS Involvement in AML Patient Treated with 5-Azacytidine. <i>Case Reports in Hematology</i> , 2014, 2014, 1-4.	0.3	3
98	Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes. <i>Hematological Oncology</i> , 2020, 38, 541-553.	0.8	3
99	Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database. <i>Leukemia Research</i> , 2021, 100, 106479.	0.4	3
100	Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis. <i>Leukemia Research</i> , 2021, 107, 106595.	0.4	3
101	Comorbidities and frailty predict outcome of patients with myelodysplastic syndromes. Should we integrate them in novel prognostic scoring systems?. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1122-1129.	0.5	3
102	Clinical Reasoning: A 51-year-old man with cervical pain and progressively deteriorating gait. <i>Neurology</i> , 2013, 80, e230-4.	1.5	2
103	Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis – A Case Report. <i>Case Reports in Hematology</i> , 2018, 2018, 1-5.	0.3	2
104	Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort study. <i>EJHaem</i> , 2020, 1, 255-261.	0.4	2
105	Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes. <i>Blood Cancer Journal</i> , 2021, 11, 30.	2.8	2
106	Solitary extramedullary plasmacytoma of the nasopharynx: The role of flow cytometry. <i>Oral Oncology</i> , 2021, 118, 105351.	0.8	2
107	Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine. <i>Epigenomics</i> , 2021, 13, 1129-1143.	1.0	2
108	Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 195.	0.8	2

#	ARTICLE	IF	CITATIONS
109	Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study. <i>Blood</i> , 2020, 136, 1-2.	0.6	2
110	Alterations In the Signaling Profile of Leukemic Progenitors Can Predict the Response of Myelodysplastic Syndrome (MDS) Patients to Azacytidine. <i>Blood</i> , 2010, 116, 2921-2921.	0.6	2
111	Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. <i>In Vivo</i> , 2022, 36, 1302-1315.	0.6	2
112	C016 Expression analysis of proteins involved in the Non Homologous End Joining DNA repair mechanism, in the bone marrow of adult de novo myelodysplastic syndromes. <i>Leukemia Research</i> , 2009, 33, S40-S41.	0.4	1
113	Response to $^{18}$ F-PET after response to R-CHOP in primary mediastinal large B-cell lymphoma $^{TM}$ . <i>Leukemia</i> , 2016, 30, 1800-1801.	3.3	1
114	Upregulated hypoxia inducible factor 1 $\alpha$ signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine $^{TM}$ data from the Hellenic myelodysplastic syndrome study group. <i>Hematological Oncology</i> , 2021, 39, 231-242.	0.8	1
115	Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece. <i>Blood</i> , 2019, 134, 5340-5340.	0.6	1
116	Multiple osteolytic lesions due to Double-Expressor Primary non-Hodgkin Lymphoma of the Bone. <i>Autopsy and Case Reports</i> , 2020, 10, e2020141.	0.2	1
117	P130 Treatment of intermediate and high risk myelodysplastic syndrome patients with azacytidine. The Hellenic experience. <i>Leukemia Research</i> , 2009, 33, S134-S135.	0.4	0
118	Cytokine profile alterations in Cutaneous T-cell Lymphoma cell lines after Lenalidomide and/or Bortezomib treatment. <i>European Journal of Cancer</i> , 2018, 101, S13.	1.3	0
119	Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group. <i>Leukemia Research</i> , 2018, 71, 55-59.	0.4	0
120	$\beta$ -Erdheim $^{TM}$ Chester Disease and Acute Myeloid Leukemia with Mutated $\beta$ -NPM1 $^{TM}$ in a Patient with Clonal Hematopoiesis: A Case Report $^{TM}$ . <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11689-11695.	1.0	0
121	Discontinuation of the renin $^{TM}$ angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072095829.	1.1	0
122	Clinical Characteristics and Prognostic Factors of Mature T-Cell Lymphomas. A Single Center Experience on 39 Cases.. <i>Blood</i> , 2005, 106, 4652-4652.	0.6	0
123	The Levels of a G-CSF-Inducible pSTAT3+pSTAT5+ Subpopulation of MDS Progenitors with Leukemic Stem Cell Phenotype Predict the Response to Azacytidine. <i>Blood</i> , 2012, 120, 3795-3795.	0.6	0
124	Expression Of CD25 Antigen On CD34+ Cells Is An Independent Predictor Of Survival In Late Stage MDS Patients Treated With Azacytidine. <i>Blood</i> , 2013, 122, 1508-1508.	0.6	0
125	Distinct Profile and Epigenetic Modulation Of STAT Signaling In FOXP3+ T Regulatory Cells Among The Various MDS Subtypes. <i>Blood</i> , 2013, 122, 1509-1509.	0.6	0
126	The Role of PET/CT Scan in Primary Gastric Lymphomas. , 2016, , 251-256.		0

#	ARTICLE	IF	CITATIONS
127	Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry. <i>Blood</i> , 2018, 132, 3107-3107.	0.6	0
128	The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 5427-5427.	0.6	0
129	Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group. <i>Blood</i> , 2019, 134, 5423-5423.	0.6	0
130	Molecular Mechanisms of Primary Resistance to Azacytidine in MDS/AML Patients - Data of the Hellenic MDS Study Group. <i>Blood</i> , 2019, 134, 5403-5403.	0.6	0
131	Modulation of the IL-6/STAT3 Signaling Axis in CD4+ T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 2988-2988.	0.6	0
132	DNA Repair Genes' Expression Abnormalities in De Novo Acute Myelogenous Leukemia (AML): Implications for Targeted Treatment. <i>Blood</i> , 2019, 134, 5176-5176.	0.6	0
133	Acute cerebral ischemia with underlying myelodysplastic syndrome mimicking vaccine-induced immune thrombotic thrombocytopenia. <i>European Journal of Neurology</i> , 2021, , .	1.7	0